CoChat
Sign Up
Cited by 60Maternal Mental Health During Pregnancy and PostpartumOpioid Use Disorder TreatmentPrenatal Substance Exposure Effects

Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes

Open access
Benningfield, Margaret M., Dietrich, Mary S., Jones, Hendrée E., Kaltenbach, Karol, Heil, Sarah H., Stine, Susan M., Coyle, Mara G., Arria, Amelia M. +3 more·2012·Addiction
DOI 10.1111/j.1360-0443.2012.04041.xPMC PMC4315620
Open this paper in CoChat — free account

Abstract

Aims: To examine the relationship of anxiety and depression symptoms with treatment outcomes (treatment discontinuation, rates of ongoing use of illicit drugs and likelihood of preterm delivery) in opioid‐dependent pregnant women and describe their use of psychotropic medications. Design and setting: Secondary data analysis from a randomized clinical trial of treatment for opioid dependence during pregnancy. Participants: A total of 175 opioid‐dependent pregnant women, of whom 131 completed treatment. Measurements: Symptoms of anxiety and depression were captured with the 15‐item Mini International Neuropsychiatric Interview (MINI) screen. Use of illicit drugs was measured by urine drug screening. Preterm delivery was defined as delivery prior to 37 weeks' gestation. Self‐reported use of concomitant psychotropic medication at any point during the study was recorded. Findings: Women reporting only anxiety symptoms at study entry were more likely to discontinue treatment [adjusted odds ratio (OR) = 4.56, 95% confidence interval (CI): 1.91–13.26, P = 0.012], while those reporting only depression symptoms were less likely to discontinue treatment (adjusted OR = 0.14, 95% CI: 0.20–0.88, P = 0.036) compared to women who reported neither depression nor anxiety symptoms. No statistically significant between‐group differences were observed for ongoing illicit drug use or preterm delivery. A majority (61.4%) of women reported use of concomitant psychotropic medication at some point during study participation. Conclusions: Opioid agonist‐treated pregnant patients with co‐occurring symptoms of anxiety require additional clinical resources to prevent premature discontinuation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2012.04041.x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Women with opioid use disorder have high rates of co-occurring mental health conditions, with depression and anxiety conditions ranging as high as 65-75%.

    “Women with OUD have high rates of co-occurring mental health conditions, with depression and anxiety conditions ranging as high as 65–75% [7–9].”

    From Mindful moms: acceptability and impact of co-designed and digitally delivered video meditations for pregnant and parenting women with opioid use disorder (2025) · cites this paper as [8]

    The Introduction reports co-occurring anxiety and depression rates of 65–73%, close to the cited 65–75%. But that figure applies to clinical samples of opioid-dependent pregnant women; the citing sentence extends it to women with OUD generally. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 21 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Benningfield, M. M., Dietrich, M. S., Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Fischer, G., & Martin, P. R.
Affiliations
  • Vanderbilt University (US)
  • Johns Hopkins University (US)
  • Thomas Jefferson University (US)
  • University of Vermont (US)
  • Wayne State University (US)
  • Brown University (US)
  • University of Maryland, College Park (US)
  • Department of Psychology University of Maryland College Park MD USA
  • Medical University of Vienna (AT)
Corresponding author
Benningfield, Margaret M.
ORCID
Venue
Addiction
Publisher
Wiley
Published
2012-10-29
Volume
107
Issue
S1
Pages
74-82
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
DOI
10.1111/j.1360-0443.2012.04041.x
PMC
PMC4315620
OpenAlex
W1764055921
Cited by
60
References
21
Citations by year
2026: 2 · 2025: 6 · 2024: 5 · 2023: 1 · 2022: 4 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
1.85
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Addiction (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Academy of Child and Adolescent Psychiatry
  • Brown University
  • Government of Ontario
  • National Institute on Drug Abuse (R01 DA15832, R01DA015778, R01DA 017513, R01DA015764, R01DA015713, R01DA015832, R01DA015741, R01DA015738, R01DA018410, R01DA018417, K12DA000357)
  • National Center for Research Resources (M01-RR-109, M01RR000095, M01RR000109, M01-RR-00095, UL1RR024975)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
Keywords
opioid use disorder, pregnancy, anxiety symptoms, depressive symptoms, treatment discontinuation, illicit drug use, preterm birth, psychotropic drug use, opioid substitution therapy, maternal substance use
MeSH terms
Adolescent, Adult, Analgesics, Opioid, Anxiety, Buprenorphine, Depression, Double-Blind Method, Female, Humans, Interview, Psychological, Methadone, Opioid-Related Disorders, Patient Compliance, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Severity of Illness Index, Comorbidity, Logistic Models, Treatment Outcome, Young Adult, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review